1261 related articles for article (PubMed ID: 29188510)
1. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
2. AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Hung SS; Chrysostomou V; Li F; Lim JK; Wang JH; Powell JE; Tu L; Daniszewski M; Lo C; Wong RC; Crowston JG; Pébay A; King AE; Bui BV; Liu GS; Hewitt AW
Invest Ophthalmol Vis Sci; 2016 Jun; 57(7):3470-6. PubMed ID: 27367513
[TBL] [Abstract][Full Text] [Related]
3. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
Yu W; Wu Z
Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
[TBL] [Abstract][Full Text] [Related]
4. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
[TBL] [Abstract][Full Text] [Related]
5. CRISPR Systems Suitable for Single AAV Vector Delivery.
Stevanovic M; Piotter E; McClements ME; MacLaren RE
Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox.
Senís E; Fatouros C; Große S; Wiedtke E; Niopek D; Mueller AK; Börner K; Grimm D
Biotechnol J; 2014 Nov; 9(11):1402-12. PubMed ID: 25186301
[TBL] [Abstract][Full Text] [Related]
9. Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.
Li F; Hung SSC; Mohd Khalid MKN; Wang JH; Chrysostomou V; Wong VHY; Singh V; Wing K; Tu L; Bender JA; Pébay A; King AE; Cook AL; Wong RCB; Bui BV; Hewitt AW; Liu GS
Hum Gene Ther; 2019 Nov; 30(11):1349-1360. PubMed ID: 31373227
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
11. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the native type I-B CRISPR-Cas for genome editing in a polyploid archaeon.
Cheng F; Gong L; Zhao D; Yang H; Zhou J; Li M; Xiang H
J Genet Genomics; 2017 Nov; 44(11):541-548. PubMed ID: 29169919
[TBL] [Abstract][Full Text] [Related]
13. A multifunctional AAV-CRISPR-Cas9 and its host response.
Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
[TBL] [Abstract][Full Text] [Related]
14. Engineering the Delivery System for CRISPR-Based Genome Editing.
Glass Z; Lee M; Li Y; Xu Q
Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
[TBL] [Abstract][Full Text] [Related]
15. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
Wang D; Zhang F; Gao G
Cell; 2020 Apr; 181(1):136-150. PubMed ID: 32243786
[TBL] [Abstract][Full Text] [Related]
17. The genome editing revolution: A CRISPR-Cas TALE off-target story.
Stella S; Montoya G
Bioessays; 2016 Jul; 38 Suppl 1():S4-S13. PubMed ID: 27417121
[TBL] [Abstract][Full Text] [Related]
18. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.
Kennedy EM; Cullen BR
Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096
[TBL] [Abstract][Full Text] [Related]
19. [CRISPR-Cas9 mediated genome editing in Caenorhabditis elegans].
Meng X; Zhou H; Xu S
Sheng Wu Gong Cheng Xue Bao; 2017 Oct; 33(10):1693-1699. PubMed ID: 29082717
[TBL] [Abstract][Full Text] [Related]
20. Temperature effect on CRISPR-Cas9 mediated genome editing.
Xiang G; Zhang X; An C; Cheng C; Wang H
J Genet Genomics; 2017 Apr; 44(4):199-205. PubMed ID: 28412228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]